Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women

C. Nappi, G. Colace, G. F. Di Renzo, M. Taglialatela, S. Amoroso, L. Annunziato, U. Montemagno

Research output: Contribution to journalArticlepeer-review

Abstract

In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.

Original languageEnglish
Pages (from-to)457-460
Number of pages4
JournalEuropean Journal of Clinical Pharmacology
Volume32
Issue number5
DOIs
Publication statusPublished - Sep 1987

Keywords

  • adverse effect
  • bromoergocriptine
  • domperidone
  • dopamine
  • prolactin
  • puerperal hyperprolactinaemia

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women'. Together they form a unique fingerprint.

Cite this